Cancer is one of the leading causes of human death. Many efforts have made to understand its mechanism and have further identified many proteins and DNA sequence variations as suspected targets for therapy. However, drugs targeting these targets have low success rates, suggesting the basic mechanism still remains unclear. Here, we develop a computational software combining Cox proportional-hazards model and stability-selection to unearth an overlooked, yet
Introduction
Cancer has been a leading cause of death globally. In 2018, more than 609K patients died in US. By 2030, annual new cancer cases will rise to 23.6M worldwide 1 . It is vital and urgent to understand its mechanisms toward therapy.
The current researches on cancer mechanism have mostly focused on proteincoding regions, both functional genomics and genome sequences, and have revealed hundred proteins as key oncogenes and have identified thousands of sequence variations across different cancer types [2] [3] [4] [5] [6] . Many alterations in chromosomes and phenotypes have been observed 7 . Recently studies also have explored cancer epigenetics mechanisms 8 and have identified a certain groups of noncoding RNAs associated with cancer development 9 . These mechanisms have helped to improve technologies on therapy 10 . However, cancer is still an incurable disease and drugs targeting molecular targets based on current mechanisms are rarely successful 11, 12 , suggesting that the real fundamental mechanism still remains unclear.
Here, we developed a computational software to unearth the basic cancer mechanism hidden in the massive data from TCGA database.
Results

Noncoding RNAs serve as the deadliest regulators of cancers
To investigate the deadliest regulators for cancers, we needed a software that could unbiasedly reveal the strongest genes corresponding to cancer death and a data set including all types of cancers. Conventionally, the Cox proportionalhazards regression model (coxph) has been widely employed to find cancer genes 13 , but it lacks random sampling during regression, leading to inaccurate estimations. Here, we developed an improved survival analysis software, referred as ISURVIVAL, to insert stability-selection 14 into coxph model to make results accurate (materials and methods). Implementing ISURVIVAL with julia computer language also makes it much faster than current software. The data used in this study was downloaded from The Cancer Genome Atlas (TCGA) public database, which includes 11,574 RNAseq samples and clinic data for all 36 cancer types (Table S1), which measured total 60,483 genes annotated with GRCh38.p2.v22 by TCGA (materials and methods).
To select the deadliest genes, we applied ISURVIVAL to a data matrix containing clinic time and status and each gene RNAseq data in all cancer samples and selected the top 428 significant genes with absolute coefficient >1 and pvalue<1.e-10 (materials and methods). We further ranked these 428 regulators in basis of their absolute coefficients (coef), higher coefficient, more important in regulating cancer death. Among 428, 92% were cancer inducers (coef > 1, HR>2.72), and only less than 8% were cancer repressors (coef< -1, HR< 0.37) ( Figure 1A) . Evermore, all top 30 regulators were 100% cancer inducers. Interestingly, processed-pseudogenes (p-pseudogenes) occupied more than 80% in these top 394 inducers (Figure 1B left panel) . At top 10 inducers, 6 (60%) were p-seudogenes, and top 1 was PANDAR (lincRNA) (Figure 1B right) . Consistently, previous studies also reported PANDAR as a caner inducer 15 . Among cancer repressors, lincRNAs and antisense RNA occupied 40% and 30% respectively( Figure 1C) . This suggested noncoding RNAs as the deadliest cancer regulators and pseudo-genes as primary inducers and lincRNA and antisense RNA as key repressors. This parallels with our recent study on cancer mechanism revealing noncoding RNAs as the core drivers for all types of cancer 16 .
Personal clinic variables account for variations of activated regulators
Researchers on cancer DNA sequences have attempted to find the genes with consensus variations across cancer types (disease types as described in table S1), but could not find any genes with more than 50% common mutations 6 . To test the consistence of gene activation across cancer types, we computed the coefficient of each gene in each cancer type, and found no consistence but high variation in the regulator activation. Even the top 10 inducers and repressors identified above Figure 1 , only <60% and <67% of inducers and repressors were respectively activated as inducers (coef>0) and repressors (coef<0) across cancer types (Figure 2A) . For example, the top 1 inducer, PANDAR, did not always work as an inducer, but as an inducer in only 57% cancer types and as a repressor in the rest.
We tried to find the reason for the activation variation, and examined the clinic variable effect on the variations of top 30 regulators by using canonical correspondence analysis (CCA). Clinic variables significantly affect the activation of genes. Among 7 character variables, sample type and alcohol affected most ( Figure 2B) , while smoking and BMI as the digital variables accounted for most of variances ( Figure 2C) . For example, PANDAR was positively correlated with sample type and negative correlated to race ( Figure 2B ), significantly higher in primary tumor (p=5.8e-9, t-test, Figure S1 ) and Asian (p=0.00019, figure S2 ). However, PANDAR did not seemed to respond very well cancer types and tissue ( Figure 2B ). Yet tissue type was used to classify cancer types. This at least partially explain its activation variation (only 57%) in current classification systemdisease type .
This observation above encouraged us to extend our CCA analysis to all genes and all 11 clinic variables. The whole cancer genome was clearly separated into three sections. The first positively affected by alcohol and smoking, the second by site, BMI and disease type, the third by unidentified factors (Figure 2D) . Astonishingly, alcohol served as the strongest factor altering cancer genome activation, even stronger than smoking and BMI ( Figure 2D ). This indicated that the cancer genome activation is not only based on tissues as practiced by current classification system, but, importantly, based on other personal clinical variables. Therefore, using the current cancer type info to evaluate the activation of inducers and repressors as shown in Figure 2A could be misleading. Furthermore, even the first 200 principal components (PCs) derived from principal component analysis (PCA) only accounted for 60% variances (Figure 2E) , indicating cancer genome activation varying with unexpectedly complicated personal clinic variables.
Noncoding RNAs as universal drivers for cancers
Cancer regulator activation varies with complex factors as observed above. To search the regulators universal for all types of cancers, we must concern personal clinic variables. Here, we inserted the all 11 clinic variables and the first 200 PCs as covariates into our ISURVIVAL to select regulators general for all cancers. The top 64 significant regulators (p<0.05, HR >1.1 or HR <0.9) included 65.6% inducers (HR>1.1) and 34.4% repressors (HR<0.9) (Figure 3 A) . Among inducers, p-pseudogenes dominated all profile and occupied 40% of top 10 ( Figure 3B) . As expected, these inducers were consistently activated as inducers in most cancer types, with RP11-335k5.2 activated in 83% cancer types (Figure 3C) . The overall percentage of inducer activation was significantly higher than previous one without concerning personal clinic variables shown in Figure 2A (p = 0.03151 and 0.08232 respectively for top 20 and top 10 inducers, t-test). This indicated these pseudogene-dominated inducers as universal inducers of cancers.
All universal repressors were also noncoding RNAs, including p-pseudogenes, lincRNAs, TEC, antisense and sense_intronic (Figure S3 ). Together suggested noncoding RNAs as the universal drivers for all cancers.
Noncoding RNAs serve as the deadliest hubs in cancer regulatory network
We previously established a cancer regulatory network and computed the centrality as top hubs in cancer genome. Here, we filtered these centrality with survival data (p<0.01 and HR<0.9 or HR>1.1) and obtained the deadliest hubs. More than 75% of top 491 hubs were inducers ( Figure 4A ) and all top 50 inducers as p_pseudogenes ( Figure 4B) . Moreover, lincRNAs, antisense, p_ pseudogene and sense_intronic dominated the top 50 repressors (Figure 4C ), suggesting noncoding RNAs as the deadliest centrality in cancer genome.
Noncoding RNAs as cancer biomarkers
We further examined whether noncoding RNAs work as biomarkers to discriminate cancer and normal samples. We used total 632 normal samples as normal to discriminate cancer samples of each cancer type, and employed elastic-net with stability-selection to select biomarkers for each cancer type (materials and methods). Typically, around 50 noncoding RNAs could discriminate cancer vs normal with rare error (Figure 5A) . We used the top 50 noncoding RNAs in each cancer type as biomarkers to calculate the discrimination accuracy by computing AUC (Area Under The Curve) of ROC (Receiver Operating Characteristics). Beginning with top 2 biomarkers, the AUC of each cancer type reached >90%, and with top 20 biomarkers, AUC reached stable state (>96%) for all cancer types (Figure 5B) . This indicated noncoding RNAs can be used as biomarkers to discriminate cancer types.
Discussion
Current researches on cancer drivers and mechanisms have focused on proteins and protein-relevant DNA sequences 2 . However, recent observations suggested most of these proteins as incorrect targets, which were selected from current mechanism studies 11 . This suggests that the current mechanisms are misleading. Here, we first time unearthed noncoding RNAs as the universal deadliest drivers for all types of cancers. Among noncoding RNAs, p-pseudogenes work as the primary cancer inducers. Noncoding RNAs have been reported as regulators for cancer 17 , and p-pseudogenes mutations have been found in cancers 18 , but they have not been reported as the key players replacing the protein spot in cancers. Recent reports regarding noncoding RNAs have focused on lincRNA category but have rarely demonstrated these pseudo-gene roles in cancer. Our findings here have established pseudogenes as the most important cancer regulators, instead of proteins as conventionally thought. This provides a novel mechanism and targets for cancer research and therapy and eventually make cancer curable.
One of long standing puzzle hanging in cancer researches is the universality of oncogenes. Many efforts have put into identifying the sequence consensus among these oncogenes, but no oncogene has more than 50 consensus sequences across cancer types 6 . Here, we revealed that the universal oncogenes exist in noncoding RNAs after normalizing personal clinic variables. For example, RP11-335k5.2 was consistently activated in 83% cancer types although current cancer type classification is misleading as described below.
Cancer types classified by tissue types have been used in cancer researched and therapy development 2 , yet cancer genome activation does not respond very well to tissues as shown in the present study. Surprisingly, alcohol contributes to cancer genome variations more than smoking, and these personal clinic variables such as alcohol and smoking are more important than tissue types in altering cancer genome activation. Therefore, the current cancer classification system may be misleading and should be reviewed to include personal variables to make therapy efficiently.
The current personal medicine on cancer has focused on personal DNA sequence variation 19 20 , but personal clinic variables such as alcohol, smoking and BMI significantly alter cancer genome activation. These personal variables may be more important than personal DNA sequence variation in personal medicine.
Overall, our finding based on personal clinic variables and gene expression data has established noncoding RNAs as the most important inducers and repressors for all cancers. This refreshes the concept on cancer mechanism and therapy. A, a typical cross-validation curve of noncoding RNAs as biomarkers. When total around 50 noncoding RNAs were selected, the mean cross-validated error reached minimum, and this corresponding lambda was selected as lambda.min for biomarker selections for all 30 cancer types. B, AUC of noncoding RNAs as biomarkers to discriminate 30 cancer types. When 10 noncoding RNAs as biomarkers, AUCs for most cancer types have not reached stable states, but when 20 noncoding RNAs were selected as biomarkers, all AUCs were stable, with AUC>0.96. LAML  ACC  BLCA  LGG  BRCA  CESC  CHOL  COAD  ESCA  GBM  HNSC  KICH  LIHC  LUAD  LUSC  DLBC  MESO  OV  PAAD  PCPG  PRAD  READ  SARC  SKCM  STAD  TGCT  THYM  UCS  UCEC  UVM   RP11 
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